Aripiprazole IM (Abilify) for agitation control in patients with schizophrenia: SMC review

The Scottish Medicines Consortium issued on 7th December, 2008 an advice on the aripiprazole intramuscular injection (Abilify):

Aripiprazole intramuscular injection (Abilify ) is accepted for use in NHS Scotland for the rapid control of agitation and disturbed behaviours in patients with schizophrenia when oral therapy is not appropriate.
Where aripiprazole is an appropriate antipsychotic, this new formulation provides rapid control of symptoms at an equivalent cost to solid oral dosage forms.
SMC has not recommended aripiprazole for use within NHS Scotland for the treatment of manic episodes in bipolar 1 disorder. Therefore this formulation is not recommended for the rapid control of agitation and disturbed behaviours in patients with manic episodes in bipolar 1 disorder.

Source: Scottish Medicines Consortium. Drug Advice: aripiprazole intramuscular injection (Abilify). PDF full text

Illustrated Psychopharmacology Lectures in Your Inbox

  • Mechanisms of action, adverse effects and indications of psychotropic medications.
  • Concise and illustrated presentations.¬†
  • Practical tips for mental health professionals.

laptop2


 

 

Are you a visual learner interested in learning psychopharmacology? Click here to get our videos